Euro Stoxx 50 Mar '24 (FXH24)
Seasonal Chart
Price Performance
See MorePeriod | Period Low | Period High | Performance | |
---|---|---|---|---|
1-Month | 4,757.00 +5.46% on 02/19/24 | | 5,033.00 -0.32% on 03/14/24 | +260.92 (+5.49%) since 02/15/24 |
3-Month | 4,402.00 +13.97% on 01/17/24 | | 5,033.00 -0.32% on 03/14/24 | +424.92 (+9.25%) since 12/15/23 |
52-Week | 4,034.00 +24.37% on 10/27/23 | | 5,033.00 -0.32% on 03/14/24 | +1,003.92 (+25.02%) since 03/15/23 |
Most Recent Stories
More NewsDuring his campaign, President-elect Trump said he would pull back on U.S. security relationships with Europe. European countries may need to double defense spending, according to a Bloomberg Intelligence...
Target Corporation TGT released its third-quarter fiscal 2024 results last Wednesday before the opening bell, sparking fresh debate among investors regarding the stock's future trajectory. As a well-established...
Cheniere Energy LNG, a leading exporter of natural gas, has been on a steady rise. On Friday, the stock closed at $222.60, just below its new 52-week high of $225.44 earlier that day. Over the past six...
AbbVie’s ABBV shares rose 3.0% on Friday after Leerink Partners analyst, David Risinger, upgraded his rating on the stock from Market Perform to Outperform.Excluding Friday’s movement, AbbVie stock...
Santech Holdings received a Nasdaq compliance notice due to late filing of its annual report, with plans to regain compliance.Quiver AI SummarySantech Holdings Limited received a notice of non-compliance...
Old National Bancorp and Bremer Financial Corporation announce a merger, enhancing their market presence and banking capabilities.Quiver AI SummaryOld National Bancorp and Bremer Financial Corporation...
Tesla could face challenges under Governor Gavin Newsom’s EV tax credit proposal, with market-share caps potentially excluding its top models.
Wall Street analysts expect Abercrombie to announce earnings of $2.39 per share on revenues of $1.19 billion.
Elite Pharmaceuticals Inc. (ELTP) fits nicely into the nexus of the increasing diagnoses of ADHD and the patent expiration of the branded drug Vyanse in 2023 for its treatment. Elite Pharmaceuticals Inc....
These last few weeks have been quite interesting and have brought out some intriguing comments from the investor and analyst community alike. Yet, the underlying theme, as seen by this market observer,...